Heron Therapeutics, Inc. (HRTX)
NASDAQ: HRTX · Real-Time Price · USD
1.490
0.00 (0.00%)
At close: Jan 16, 2026, 4:00 PM EST
1.498
+0.008 (0.54%)
After-hours: Jan 16, 2026, 7:07 PM EST
Heron Therapeutics Revenue
Heron Therapeutics had revenue of $38.21M in the quarter ending September 30, 2025, with 16.47% growth. This brings the company's revenue in the last twelve months to $155.10M, up 12.60% year-over-year. In the year 2024, Heron Therapeutics had annual revenue of $144.29M with 13.57% growth.
Revenue (ttm)
$155.10M
Revenue Growth
+12.60%
P/S Ratio
1.52
Revenue / Employee
$1,271,287
Employees
122
Market Cap
273.21M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 144.29M | 17.24M | 13.57% |
| Dec 31, 2023 | 127.04M | 19.37M | 17.99% |
| Dec 31, 2022 | 107.67M | 21.33M | 24.70% |
| Dec 31, 2021 | 86.35M | -2.29M | -2.59% |
| Dec 31, 2020 | 88.64M | -57.33M | -39.28% |
| Dec 31, 2019 | 145.97M | 68.49M | 88.41% |
| Dec 31, 2018 | 77.47M | 46.71M | 151.81% |
| Dec 31, 2017 | 30.77M | 29.49M | 2,305.55% |
| Dec 31, 2016 | 1.28M | - | - |
| Dec 31, 2015 | - | - | - |
| Dec 31, 2014 | - | - | - |
| Dec 31, 2013 | - | - | - |
| Dec 31, 2012 | - | - | - |
| Dec 31, 2011 | 646.00K | -655.00K | -50.35% |
| Dec 31, 2010 | 1.30M | 40.00K | 3.17% |
| Dec 31, 2009 | 1.26M | 892.00K | 241.73% |
| Dec 31, 2008 | 369.00K | -43.00K | -10.44% |
| Dec 31, 2007 | 412.00K | - | - |
| Dec 31, 2006 | - | - | - |
| Dec 31, 2005 | 5.39M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
HRTX News
- 8 days ago - Heron Therapeutics Announces Preliminary, Unaudited Q4 and Full-Year 2025 Net Revenue; ZYNRELEF® Largest Contributor to Q4 Growth - GlobeNewsWire
- 6 weeks ago - Heron Therapeutics Announces Inclusion of APONVIE® (aprepitant) Injectable Emulsion in the Newly Released Fifth Consensus Guidelines for the Management of Postoperative Nausea and Vomiting (PONV) - GlobeNewsWire
- 2 months ago - Heron Therapeutics, Inc. (HRTX) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 2 months ago - Heron Therapeutics Announces Q3 2025 Financial Results and Highlights Commercial Progress - GlobeNewsWire
- 2 months ago - Heron Therapeutics Announces Appointment of Thomas Cusack to Board of Directors - GlobeNewsWire
- 3 months ago - Heron Therapeutics to Report Third Quarter 2025 Financial Results on Tuesday, November 4, 2025 - GlobeNewsWire
- 5 months ago - Heron Therapeutics, Inc. Adopts Tax Benefits Preservation Plan to Protect NOL Assets and Shareholder Value - PRNewsWire
- 5 months ago - Heron Therapeutics, Inc. (HRTX) Q2 2025 Earnings Call Transcript - Seeking Alpha